The Journal of Urology® Home Study Course 2023 Volume 209/210.

Abstract

You have accessJournal of UrologyCME1 Jul 2023The Journal of Urology® Home Study Course 2023 Volume 209/210 View All Author Informationhttps://doi.org/10.1097/JU.0000000000003521AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail AUA CME Requirements Program Description and Objectives:The Journal of Urology® Home Study Course is a comprehensive learning activity developed by a team of educators, academicians and clinicians. After completing each lesson, the participants will be able to assess their knowledge of urology, demonstrate an increased knowledge base of urology, and apply the increased knowledge to improve quality of patient care. Target Audience:The Journal of Urology® Home Study Course is designed for practicing urologic physicians, American Board of Urology (ABU) candidates and/or residents. Estimated time to complete each lesson: 2.0 hours. Program Enrollment: Enroll by visiting AUAnet.org/JUHS. Method of participation in the learning process: Two volumes of The Journal of Urology® are published annually. Each volume is comprised of 6 issues. Five clinically relevant articles are selected by the editor to be offered for CME in each issue of The Journal. For CME credit, the participant must be enrolled in the home study course for the year, read the educational material provided, pass the corresponding online posttest with 80% accuracy, submit the online evaluation and claim CME. Please go to: AUAnet.org/JU23. Each issue is designated for a maximum of 2.0 AMA PRA Category 1 Credits™. Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation: The American Urological Association designates this enduring material for a maximum of 24.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™. Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments. Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest: Peer review for valid, evidence-based content by the AUA COI Review Work Group Attestation that clinical recommendations are evidence-based and free of commercial bias Introduction of a debate format with an unbiased moderator (pointcounterpoint) Inclusion of moderated panel discussion Publication of a parallel or rebuttal article for an article that is felt to be biased Divestiture of the relationship by faculty Recusal from controlling relevant aspects of planning Selection of alternative faculty for specific topic Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to offlabel or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses. Disclosures: A complete list of disclosures can be found at AUAnet.org/JU23Disclosures. All relevant financial disclosures from the JU Editorial Board and authors have been mitigated. Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association. Release Date: Issue month, 2023. Expiration Date: Issue month, 2026. Copyright © 2023 by American Urological Association Education and Research, Inc. Email [email protected]orgwith any questions. CME Questions for the July 2023 Issue of The Journal of Urology® 1. Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging–targeted Biopsy: A Study That Challenges the Dogma (vol. 210, pp. 117-127) Among patients with cN0 disease diagnosed with MRI-targeted-biopsy, a good candidate for discussing unilateral pelvic lymph node dissection at radical prostatectomy might be a) any patient who is a surgical candidate b) a patient with high-risk disease features (ISUP [International Society of Urological Pathology] 4-5, extracapsular extension/seminal vesicle invasion on multiparametric MRI, or PSA ≥20 ng/mL) c) a patient with extensive high-grade bilateral disease on biopsy d) a patient with organ-confined disease ISUP 2-3 on targeted biopsy and contralateral negative biopsy 2. Renal Mass Biopsy Mandate Is Associated With Change in Treatment Decisions (vol. 210, pp. 72-78) For a solitary small renal mass suspicious for cancer, current AUA guidelines recommend renal mass biopsy before which management option? a) active surveillance b) percutaneous ablation c) partial nephrectomy d) radical nephrectomy 3. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer (vol. 210, pp. 99-107) A patient enters active surveillance with Grade Group 1 prostate cancer and on a subsequent biopsy is diagnosed with Grade Group 2 disease. These factors would favor remaining on active surveillance: a) low PSA density and lack of perineural invasion b) large cribriform glands and intraductal carcinoma c) Prostate Imaging Reporting & Data System 5 MRI lesion d) percent Gleason pattern 4 approaching 50% 4. Initial Management of Indeterminate Renal Lesions in a Statewide Collaborative: A MUSIC-KIDNEY Analysis (vol. 210, pp. 79-87) Appropriate next steps for a 2.5-cm renal lesion that is indeterminate on CT imaging with contrast include any of the following except a) MRI with and without contrast b) CT with and without contrast c) repeat imaging in 3 months d) partial nephrectomy 5. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation (vol. 210, pp. 88-98) A 62-year-old man with good past health and good performance status had an elevated blood PSA test of 6.0 ng/mL. Prostate Health Index (PHI) value was 45.0. Multiparametric MRI prostate showed a 45-mL prostate with one 6-mm Prostate Imaging Reporting & Data System 3 lesion in the left transitional zone. What is the most useful parameter in informing the need of a prostate biopsy? a) PSA b) PSA density (PSA divided by prostate volume) c) PHI d) PHI density (PHI divided by prostate volume) Publication date: July 2023 Expiration date: July 2026 Answers to questions and CME credit can be obtained at AUAnet.org/JU23. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 210Issue 1July 2023Page: 227-228 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Expand All Answers to questions and CME credit can be obtained at AUAnet.org/JU23. Advertisement Advertisement PDF downloadLoading ...